Holen Sie sich die Stockscreener-App
1.24
3.13%
-0.04
Schlusskurs vom Vortag:
$1.28
Offen:
$1.27
24-Stunden-Volumen:
32,475
Relative Volume:
0.29
Marktkapitalisierung:
$38.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.70M
KGV:
-0.6078
EPS:
-2.04
Netto-Cashflow:
$-61.05M
1W Leistung:
+2.48%
1M Leistung:
-10.79%
6M Leistung:
+20.39%
1J Leistung:
-50.00%
1-Tages-Spanne:
$1.24
$1.29
1-Wochen-Bereich:
$1.18
$1.325
52-Wochen-Spanne:
$0.87
$3.07
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Firmenname
An 2 Therapeutics Inc
Sektor
Branche
Telefon
(650) 331-9090
Adresse
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Vergleichen Sie ANTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.25 | 38.23M | 0 | -60.70M | -61.05M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.67 | 125.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.68 | 60.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.99 | 36.45B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
231.77 | 30.16B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.36 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Alle ansehen
An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten
Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire
Cyrano Therapeutics Completes Enrollment in Phase 2 FLAVOR Trial of CYR-064 for Post-Viral Smell Loss - Yahoo Finance
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study - MarketScreener
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - GlobeNewswire
NMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit - The Malaysian Reserve
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting - Yahoo Finance
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy - GlobeNewswire
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - BioSpace
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - Yahoo Finance
Tenaya Therapeutics Announces Late Breaker Presentation - GlobeNewswire
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Yahoo Finance
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Yahoo Finance
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Quantisnow
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial - Stock Titan
Breakthrough: Leap's Colorectal Cancer Drug Delivers 32% Higher Response Rate in Latest Trial - Stock Titan
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - Yahoo Finance
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - The Manila Times
Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials - Nasdaq
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors - Yahoo Finance
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - GlobeNewswire
Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - Yahoo Finance
Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia - Yahoo Finance
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - Yahoo Finance
Dyne Therapeutics Announces New Long-Term Clinical Data - GlobeNewswire
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial - PR Newswire
Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer - Business Wire
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - Business Wire
Latest News | Sun Pharma Shares Rise over 2 Pc as Company to Acquire Checkpoint Therapeutics - LatestLY
Sun Pharma Shares Gain 2% on Plans to Acquire Checkpoint Therapeutics - EquityPandit
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - Yahoo Finance
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open - Yahoo Finance
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - BioSpace
Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 - Insider Monkey
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey
Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 - Yahoo Finance
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial resultsICYMI - Proactive Investors USA
Silver Bullet Therapeutics Announces Podcast Scheduled to Air on March 2, 2025 - Yahoo Finance
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - Yahoo Finance
Medicenna Therapeutics Corp. - Baystreet.ca
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer - GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 - GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients - Yahoo Finance
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance
Finanzdaten der An 2 Therapeutics Inc-Aktie (ANTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
An 2 Therapeutics Inc-Aktie (ANTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chanda Sanjay | Chief Development Officer |
Jan 03 '25 |
Sale |
1.34 |
2,957 |
3,965 |
29,824 |
| Prior Stephen David | Chief Strategy Officer |
Jan 03 '25 |
Sale |
1.34 |
2,029 |
2,721 |
33,313 |
| Eizen Joshua M | See Remarks |
Jan 03 '25 |
Sale |
1.34 |
9,663 |
12,958 |
116,672 |
| Readnour Robin Shane | Director |
Dec 09 '24 |
Buy |
1.43 |
30,772 |
43,984 |
647,573 |
| Readnour Robin Shane | Director |
Dec 06 '24 |
Buy |
1.45 |
19,228 |
27,795 |
629,090 |
| Readnour Robin Shane | Director |
Dec 10 '24 |
Buy |
1.49 |
10,000 |
14,930 |
652,573 |
| Readnour Robin Shane | Director |
Nov 27 '24 |
Buy |
1.42 |
50,000 |
70,840 |
622,573 |
| Readnour Robin Shane | Director |
Nov 26 '24 |
Buy |
1.39 |
25,000 |
34,845 |
597,573 |
| Zakrzewski Joseph S | Director |
Nov 27 '24 |
Buy |
1.40 |
2,000 |
2,800 |
125,199 |
| Readnour Robin Shane | Director |
Nov 19 '24 |
Buy |
1.04 |
150,000 |
155,258 |
560,073 |
0.36%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):